Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China
The collaboration strengthens
"Founded by seasoned executives with deep global and regional development experience and with a growing portfolio of potentially complementary cancer therapies,
"We are thrilled to enter into this collaboration with
Subject to the terms of the agreement,
Pursuant to the terms of the agreement,
Avapritinib is an orally available, potent and highly selective inhibitor of KIT and PDGFRα. Preclinical data have shown that avapritinib is active across a broad spectrum of KIT and PDGFRα mutations, including KIT D816V, PDGFRα D842V and KIT exon 17 mutations, for which there are limited or no effective treatment options.
BLU-554 is an orally available, potent, irreversible inhibitor of FGFR4. BLU-554 was specifically designed by
BLU-667 is an orally available, potent and highly selective inhibitor designed to target RET fusions, mutations and predicted resistance mutations.
CS1001 is an investigational monoclonal antibody directed against PD-L1 being developed by
A first-in-human Phase I study (CS1001-101) has been conducted by
Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other disease driven by the abnormal activation of kinases.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the collaboration and license agreement between
View original content with multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-and-cstone-pharmaceuticals-announce-exclusive-collaboration-and-license-agreement-to-develop-and-commercialize-avapritinib-blu-554-and-blu-667-in-greater-china-300658810.html
Blueprint Medicines Investor and Media Relations Contacts: Kristin Hodous, 617-714-6674, KHodous@blueprintmedicines.com or Jim Baker, 617-844-8236, JBaker@blueprintmedicines.com; CStone Pharmaceuticals Media and Investor Relations Contacts: Bing Yuan, +86-21-61047718, email@example.com